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a  b  s  t  r  a  c  t
Introduction: Worldwide about 30% of HIV-infected patients are coinfected with HCV or HBV.
The  HIV/HCV coinfection is more common in individuals who have a history of drug addic-
tion. The aims of this study were to assess the HCV and HBV prevalence in HIV-infected
patients and analyze their characteristics.
Methods: We  considered the new HIV diagnoses notiﬁed by the regional surveillance
system of Tuscany from 2009 to 2013. Descriptive analyses were conducted on the socio-
demographic characteristics, routes of transmission, and reason to perform the test. In
coinfected patients we assessed the risk for being late presenter (LP) or the risk of having
AIDS.
Results: In 5 years of surveillance a total of 1354 new HIV diagnoses were notiﬁed: 1188
(87.7%) were HIV alone, 106 (7.8%) HIV/HCV, 56 (4.1%) HIV/HBV, and 4 (0.33%) HIV/HCV/HBV.
The  main risk factor was injection drug use in 52.8% of HCV/HIV cases, while in HIV/HBV
patients the main risk factor was sexual exposure. HIV/HBV coinfected patients showed
worse clinical and immunological features than HIV and HIV/HCV patients: 78.6% had CD4
count  less than 350 mm−3 (vs. 54.6% and 62.1%, respectively) and 39.4% had AIDS (vs 20.7%
and  7.6%). The risk for being LP triples for HIV/HBV (OR 2.98; 95% IC: 1.56–5.70) than patients
with  HIV alone.
Conclusions: We  have observed less advanced disease in HIV and HCV-HIV patients com-
pared with HBV–HIV coinfected patients. Moreover, our results show a higher prevalence of
HIV/HCV among drug addicts and in the age-group 35–59, corresponding to those born inyears considered most at risk for addiction. This study also conﬁrms the ﬁnding of a less
advanced HIV disease in HIV/HCV coinfected patients.
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IntroductionThe Acquired Immune Deﬁciency Syndrome (AIDS), reported
for the ﬁrst time in literature in 1981, represents the ﬁnal
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clinical stage of infection by the human immunodeﬁciency
1The advent of Highly Active Anti-Retroviral Therapy
(HAART) has changed the natural history and epidemiology of
HIV infection. In particular, the mortality rate has decreased
e under the CC BY-NC-ND license (http://creativecommons.org/
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s a consequence of the reduction in the number of people
ho  develop the condition of AIDS. In 2012, people living with
IV infection or AIDS were 35 million worldwide, while the
ew diagnoses were about 2.3 million, with a decrease of 33%
ompared to 2001, when new infections were approximately
.4 million.2
Sub-Saharan Africa is the most affected region. Recently, 1
illion new diagnoses were reported. South and South-East
sia reported 270 thousand new diagnoses. In Europe, HIV
nfection remains a problem of major public health impor-
ance. Italy, in 2012, reported 3853 new diagnoses of HIV
nfection and 715 cases of AIDS, amounting to an incidence
ate of 6.5 and 1.7 cases per 100,000 inhabitants, respectively.
hese rates, although lower than the European average, are
igher than the average of other European Union and Euro-
ean Economic Area (EU/EEA) countries.3
Worldwide, about 1 million deaths per year are attributed
o hepatitis B or C viral infections (HBV or HCV). This repre-
ents 2.7% of all cause mortality. The most common causes
nclude hepatocellular carcinoma. Moreover, 57% of cases of
iver cirrhosis and 78% of liver cancer are caused by HBV and
CV.4 HBV, HCV, and HIV share the same transmission routes.
t has been estimated that worldwide about 30% of people with
IV are coinfected with HCV or HBV.5 Usually, the HIV/HCV co-
nfection is more  common in individuals who have a history
f drug addiction.6 Several studies have also demonstrated
hat such coinfections present a major risk for liver ﬁbrosis
rogression and subsequent evolution to cirrhosis.7
Based on these premises, the objectives of this study were
o evaluate the prevalence of HIV/HCV and HIV/HBV coinfec-
ions in Tuscany and to analyze their characteristics.
ethods
n Italy, AIDS was declared a nationally notiﬁable infectious
isease by Ministerial Decree No. 288 of November 28, 1986 and
as subsequently subjected to special notiﬁcation by ﬁlling in
 special form. In 2008, new diagnoses of HIV infections were
lso subjected to mandatory notiﬁcation.
In Tuscany, the management of the HIV regional surveil-
ance system has been improved since 2009 and requiring
otiﬁcation of new HIV diagnoses.
In this study, we considered the cases of new HIV diagnoses
otiﬁed in Tuscany from 2009 to 2013 to the Regional Surveil-
ance System. This dataset contained information about
atient gender, age, nationality, mode of transmission, rea-
on for being tested, CD4 lymphocytes count, HIV viral load,
nd AIDS diagnosis. We analyzed the prevalence of coinfec-
ion with HBV (based on the presence of antigen surface
 HBsAg), HCV (based on the presence of anti-HCV anti-
ody, which identiﬁes people who have been infected with
he virus), or both. We  considered the following clinical and
mmunological conditions: (1) late presentation (LP): persons
resenting for care with a CD4 count below 350 cells/L or with
n AIDS-deﬁning event (such as bacterial infections, candidia-
is, cryptococcosis, cytomegalovirus retinitis, Kaposi sarcoma,
ymphoma), irrespective of CD4 cell count; (2) presentation
ith advanced HIV disease (AHD): persons presenting for care
ith a CD4 count below 200 cells/L or with an AIDS-deﬁning6;2 0(4):330–334 331
event, regardless of the CD4 cell count8; and (3) AIDS condi-
tion, deﬁned as having HIV and an opportunistic infection,
regardless of the CD4 cell count.
Socio-demographic characteristics, risk factors, reasons
for being HIV tested, and the clinical and immunological
features of patients were analyzed in the following four
groups of patients: HIV monoinfection, HIV/HBV, HIV/HCV,
and HIV/HBV/HCV infected patients. A chi-square test was
performed to analyze the association between each variable
and the condition of coinfection.
Multivariate logistic regression analysis was used to
explore if the coinfection conditions were associated with LP,
AHD or AIDS, adjusting for gender, age, nationality, and risk
factors.
Statistical analyses were performed using STATA SE 12.0
statistical software.
Results
In ﬁve years of surveillance (2009–2013), 1402 new HIV diag-
noses were notiﬁed in Tuscany, with an incidence rate of 7.6
per 100,000 residents. Information on HBV or HCV coinfec-
tion was available for 1354 (96.6% of the total number of the
new HIV diagnoses) HIV infected patients: 1188 (87.7%) were
monoinfected, 106 (7.8%) were coinfected with HIV/HCV, 56
(4.1%) with HIV/HBV, and 4 (0.3%) with HIV/HCV/HBV.
In the HIV monoinfected, HIV/HBV, and HIV/HCV groups
20.9%, 14.3%, and 18.9% were female, respectively (Table 1).
Italian nationality was signiﬁcantly different in three groups
of patients: 91.5% of HIV/HCV patients, 60.7% of HIV/HBV,
and 74.8% of HIV monoinfection. Most (73.6%) of the HIV/HCV
patients were diagnosed in the 35–59 age group (median age
43), compared to 50.0% of HIV/HBV patients (median age 38)
and 55.6% of HIV monoinfected patients (median age 39).
Among HIV/HCV cases 52.8% had been infected through
injection drug use. In HIV/HBV and HIV monoinfected
patients, the main risk factor for viral transmission was sexual
exposure (Fig. 1).
HIV testing was mainly done due to suspicion of a dis-
ease or HIV-related clinical signs of acute infection, especially
in HIV/HBV patients (62.5%). The test was performed sponta-
neously due to the perception of the risk of infection by 14.3%
of HIV/HBV, 26.7% of HIV monoinfected, and 21.7% of HIV/HCV
patients. Moreover, among HIV/HCV patients, 7.6% and 12.3%
of the patients performed the test in prison or because it was
offered by the Service for Drug Addiction (Table 2).
HIV/HBV patients presented a worse clinical and immuno-
logical picture compared with HIV monoinfected and HIV/HCV
patients. HIV viral load of HIV/HBV and HIV/HCV coinfected
patients was not signiﬁcantly different. In HIV/HBV patients
the proportions of LP (78.6%) and AHD (64.3%) were higher
compared to HIV/HCV (61.3% and 41.5%) and HIV monoin-
fected patients (55.2% and 39.6%). AIDS was diagnosed in
39.3%, 20.7%, and 7.6% of HIV/HBV, HIV monoinfected and
HIV/HCV patients, respectively.
Adjusting for gender, age, nationality, and risk factors, the
HIV/HBV patients showed a higher risk to be LP compared
to HIV monoinfected patients (OR 3.04; 95% CI: 1.55–5.95).
The risk of having AHD was also higher in HIV/HBV patients
(OR 2.84; 95% CI: 1.57–5.14) compared to HIV monoinfected
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Table 1 – Socio-demographic characteristics of HIV, HIV/HBV, HIV/HCV, HIV/HCV/HBV patients notiﬁed in Tuscany
(2009–2013).
Socio-demographic characteristics HIV HIV/HBV HIV/HCV HIV/HCV/HBV p-value
n % n % n % n %
Gender
Male 940 79.1 48 85.7 86 81.1 3 75.0 0.647
Female 248 20.9 8 14.3 20 18.9 1 25.0
Age group
0–16 4  0.3 0 – 0 – 0 – 0.050
17–34 427 35.9 21 37.5 20 18.9 1 25.0
35–59 660 55.6 28 50.0 78 73.6 3 75.0
≥60 97 8.2 7 12.5 8 7.6 0 –
Nationality
Italian 889 74.8 34 60.7 97 91.5 4 100.0 0.000
Foreign 299 25.2 22 39.3 9 8.5 0 –
Table 2 – Reasons for getting an HIV test in HIV, HIV/HBV, HIV/HCV, HIV/HCV/HBV adult patients notiﬁed in Tuscany
(2009–2013).
Reasons for getting an HIV testa HIV HIV/HBV HIV/HCV
Hypothesis of an HIV-related pathology 38.2 46.4 31.1
Hypothesis of a sexually transmitted disease 9.0 12.5 4.7
Situation of acute infection 7.9 3.6 8.5
Total number tested for acute infection/STD/HIV related disease 55.2 62.5 44.3
Spontaneously 26.7 14.3 21.7
Gynecological consultation during pregnancy 4.1 3.6 2.8
Offered after informative campaign 1.9 1.8 0.9
Offered by the Service for Drug Addiction 0.9 1.8 12.3
Carried out before surgery 1.4 3.6 –
Offered in prison 0.6 1.8 7.6
Offered before blood/organ/tissue/sperm donation 1.9 1.8 –
Offered by family consultant/gynecologist (if not pregnant) 0.7 – –
No risk factor 0.4 – –
Other 
a Multiple responses.
patients. No statistically signiﬁcant difference was found
between HIV/HCV and HIV monoinfected patients (Table 3).
Compared to HIV monoinfected patients, HIV/HBV patients
had a higher risk of AIDS (OR 2.44; 95% CI: 1.35–4.43) while
the risk of HIV/HCV patients seemed lower (OR 0.23; 95% CI:
0.10–0.52).
DiscussionTo our knowledge, this study shows for the ﬁrst time that the
clinical and immunological features of HIV/HBV coinfected
Table 3 – Multivariate logistic regression analysis. Estimate of r
AIDS. Adult patients notiﬁed in Tuscany. 2009–2013.
Late presenter Adva
%a OR IC 95% % OR
HIV 55.2 1.00 – 39.6 1.0
HIV/HBV 78.6 3.04 1.55–5.95 64.3 2.8
HIV/HCV 61.3 1.24 0.75–2.05 41.5 0.8
Odds ratio and conﬁdence intervals at 95% adjusted by gender, age, nation
a The total amount of the three conditions is not 100%, because each grou6.0 7.1 10.4
patients are more  severe compared to those co-infected with
HIV/HCV and HIV monoinfected patients at the time of HIV
diagnosis. HIV was diagnosed either in prison or by the Ser-
vice for Drug Addiction in almost 20% of HCV/HIV coinfected
patients, which may have contributed to the less advanced
HIV disease in this population. In fact, drug use is the main
risk factor for transmission in this group of patients. Moreover,
about 15–45% positive for anti-HCV antibodies spontaneously
clear the virus.
The HIV/HBV co-infection was common in foreigners and
they had both age and risk factors similar to those who
elative risk for HIV, HIV/HBV, HIV/HCV to be LP, AHD or
nced HIV disease AIDS
 IC 95% % OR IC 95%
0 – 20.7 1.00 –
4 1.57–5.14 39.3 2.44 1.35–4.43
1 0.49–1.34 7.6 0.23 0.10–0.52
ality, mode of transmission.
p may be inside other groups.














Fig. 1 – HIV transmission route in HIV, HIV/HBV, HIV/HCV,



































ere HIV monoinfected. However, these patients had a worse
mmunological picture at the time of HIV diagnosis compared
o HIV/HCV co-infected patients, probably because the sexual
ransmission was the main risk factor in HIV/HBV coinfected
atients, with subsequent less perception of the infection
ransmission risk, therefore they only performed the test after
xperiencing HIV-related symptoms. Moreover, they were at
igher risk of having LP, AHD, or AIDS compared to HCV coin-
ected patients. According with these ﬁndings, recent studies
ointed out that HBV infection complicates the management
f HIV infection. In fact, patients with chronic HBV at the time
f HIV diagnosis had an impaired CD4 recovery, an acceler-
ted immunologic deterioration, and a signiﬁcantly higher risk
f an AIDS or death event.9,10 This is similar to HIV induced
mpairment of HBV, which in turn inﬂuences negatively the
ourse and progression of HIV disease.
We also found a high prevalence of HBV–HIV coinfection
n foreigners. In 1991, Italy initiated universal HBV vaccina-
ion for all newborns and 12-year-old adolescents. Since the
accination programs had a different pace in developing coun-
ries, the high prevalence among foreigners could be due to
on-compliance with Italy’s vaccination program.11
The introduction of blood-screening for HCV in the early
990s strongly decreased HCV transmission from blood
ransfusions. Our data also conﬁrm the results of several
tudies that showed a high prevalence of HCV coinfection in
IV-infected intravenous drug users.6,12,13 Moreover, this co-
nfection was more  prevalent in patients aged 35–59 years,
orresponding to those born in the years at major risk for drug
buse. Baby boomers are people born during the post-World
ar II, approximately between the years of 1946 and 1964. HCV
nfection and fatty liver disease are more  common in the Baby
oomers and may play a more  dominant role as they age,14
robably because aging of the baby boomer cohort will soon6;2 0(4):330–334 333
comprise a large proportion of persons who have used illicit
drugs in their lifetimes. A recent cross-sectional study con-
ducted in Brazil showed that the prevalence rate of HIV-HCV
coinfection was 6.9% among 848 HIV-infected patients receiv-
ing care at reference centers in the Midwest Region of Brazil.15
This also conﬁrms the less advanced disease in these patients,
probably due to a higher perceived risk of disease, which could
lead them to test earlier. Even after adjusting for gender, age,
nationality, and transmission route, we were able to show that
HIV/HCV had a lower risk of having AIDS diagnosis at the time
of detection of HIV infection compared to HIV monoinfected
patients.
HCV screening in HIV-infected patients is highly recom-
mended in order to treat HCV infection when appropriate.
Currently, interferon-free treatment regimens are available
and they require shorter periods of treatment (3 months).
These regimens are free of the associated substantial side
effects, and preliminary results suggest that these treat-
ments are also effective in patients with cirrhosis (some for
6 months).16
In conclusion, our data show that both age and risk fac-
tors for HIV/HBV coinfected patients are similar to that of HIV
monoinfected patients. Moreover, the prevalence of HBV was
higher in HIV-infected foreigners compared to HIV-infected
Italian patients. Future pathogenesis studies are needed to
conﬁrm the higher risk for LP, AHD, and AIDS in HBV coin-
fected patients. Our data also conﬁrm a higher prevalence
of HIV/HCV infections among drug addicts, especially in the
35–59 age group, corresponding to those born in the years con-
sidered most at risk for drug abuse. This also suggests that the
higher perceived risk of disease leads to earlier HIV testing
compared to HIV/HBV patients.
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